C
Core Biogenesis
Core Biogenesis produces pharma-grade recombinant proteins with its plant-based bioproduction platform. Our first products are growth factors used for Cell Therapy manufacturing and Cultivated meat…
About Core Biogenesis
Developer of bioproduction technologies designed to use plants as biofactories to scale the production of high-value bioproducts. The company's ultra-scalable bioproduction as a service (UBaaS) platform accelerates mass production and isolates molecules to a specific plant compartment, making extraction faster, and more scalable and it also offers proprietary gene editing and plant biotechnology to produce GF(Growth Factors) molecules used in the clean meat and cell therapy industries, which regulate the growth, division, and survival of cells, enabling clients to increase yields while driving down costs. Keywords: Pharmaceuticals and Biotechnology, Bioproduction Facility, Biotech Company, Biotechnology Processing, Cytokines Synthesis, Growth Factoring Molecules, Protein Production, Recombinant Molecule Production, Recombinant Protein Bioproduction.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Strasbourg, France
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 78.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biomaterials, Molecular, Synthetic Biology, Spinout, Alternative Protein, Sustainable Development Goals, EIC, Climate Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Mar 2022 | $1.2M | — | European Innovation Council | — |
| SERIES A✓Equity / VC | Mar 2022 | $11M | $44M | Blue Horizon · Blue Horizon Equity · XAnge · Entrepreneurs First | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Core Biogenesis is 310 monthly website visits, down 47.5% over the last three months. Core Biogenesis's team grew 3.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Plug and Play
XAnge
Entrepreneurs First
European Innovation Council
Series A3 investors entered at this stage
- BEBlue Horizon Equity
Blue Horizon
Thia Ventures
Other known investors8 additional known investors
INRAE
Agoranov
Evan Kervella- JBJoël Besse
Martin Weber
Olivier Rameil
SEMIA
Siparex
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Core Biogenesis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Core Biogenesis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.